Skip to main content

Table 1 PH Cox regression univariate analyses for the association of gene SPAG5 with cancer progression and prognosis in different breast cancer subtypes

From: The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy

Breast cancer subtypes

RFS

OS

DMFS

n

HR

P-value

n

HR

P-value

n

HR

P-value

Total

3557

1.72 (1.54–1.94)

< 0.001

1117

1.86 (1.46–2.37)

< 0.001

1610

1.88 (1.53–2.32)

< 0.001

ER status

 ER+

2766

1.77 (1.55–2.03)

< 0.001

377

2.74 (1.74–4.33)

< 0.001

577

2.89 (1.95–4.29)

< 0.001

 ER-

788

1.03 (0.82–1.28)

0.81

142

0.91 (0.52–1.6)

0.74

170

1.04 (0.62–1.73)

0.89

PR status

 PR+

525

2.02 (1.38–2.94)

< 0.001

0

–

–

122

1.35 (0.41–4.46)

0.62

 PR-

483

1.42 (1.04–1.93)

0.027

2

–

–

95

2.24 (1.04–4.85)

0.035

HER2 status

 HER2+

168

0.78 (0.46–1.32)

0.36

28

0.59 (0.19–1.83)

0.36

66

1.54 (0.61–3.91)

0.36

 HER2-

756

1.78 (1.36–2.34)

< 0.001

62

0.92 (0.32–2.62)

0.87

82

2.43 (0.63–9.39)

0.18

ER+/PR+/HER2+

76

1.53 (0.33–7.09)

0.58

36

3.54 (0.41–30.58)

0.22

45

1.83 (0.36–9.47)

0.46

ER+/PR−/HER2+

26

0.47 (0.09–2.35)

0.35

–

–

–

–

–

–

ER+/PR+/HER2-

339

2.41 (1.48–3.93)

< 0.001

39

2.04 (0.18–22.51)

0.55

79

1.66 (0.33–8.22)

0.53

ER+/PR−/HER2-

77

1.47 (0.65–3.33)

0.35

–

–

–

–

–

–

ER−/PR−/HER2-

255

1.45 (0.9–2.34)

0.13

–

–

–

43

3.33 (0.67–16.58)

0.12

LN status

 LN+

945

1.63 (1.3–2.03)

< 0.001

197

1.38 (0.84–2.28)

0.2

337

1.74 (1.14–2.65)

0.009

 LN-

1813

1.67 (1.4–1.99)

< 0.001

425

2.41 (1.56–3.74)

< 0.001

896

2.42 (1.79–3.27)

< 0.001

Grade

 1

308

2.52 (1.4–4.54)

0.0014

135

2.45 (0.86–6.96)

0.083

172

2.35 (0.94–5.84)

0.059

 2

724

1.9 (1.45–2.49)

< 0.001

287

2.92 (1.76–4.86)

< 0.001

495

1.93 (1.34–2.78)

< 0.001

 3

723

1.17 (0.91–1.51)

0.23

347

0.9 (0.6–1.34)

0.6

391

1.12 (0.77–1.64)

0.54

TP53 status

 Mutated

188

0.91 (0.57–1.47)

0.71

111

0.95 (0.45–2.04)

0.91

83

0.8 (0.33–1.93)

0.62

 Wild type

273

1.49 (0.97–2.28)

0.064

187

2.16 (1.1–4.23)

0.022

109

3.44 (1.44–8.22)

0.0031

  1. RFS Relapse free survival, OS Overall survival, DMFS Distant metastasis-free survival, HR Hazard ratio, − Ddata not available, LN Lymph node
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us